PET developer Positron of Houston has completed the due diligencephase of its planned acquisition of GE Medical Systems' PET business(SCAN 7/31/96). Positron said it is in the latter stages of securingfinancing for the deal, which it expects to have in
PET developer Positron of Houston has completed the due diligencephase of its planned acquisition of GE Medical Systems' PET business(SCAN 7/31/96). Positron said it is in the latter stages of securingfinancing for the deal, which it expects to have in place in fourto six weeks. The company said it hopes to close the deal by theend of this year, after shareholder approval is received.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.